Quince Therapeutics (QNCX) announced that the company has completed enrollment in its pivotal Phase 3 NEAT clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics initiated with a Buy at Lucid Capital
- Quince Therapeutics Raises $11.5M in Private Placement
- Quince Therapeutics prices up to $22M placement of securities
- Quince Therapeutics Approves Key Proposals at Annual Meeting
- Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial